DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2264391/moderna-mrna-gears-up-for-q1-earnings-here-s-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_article-2264391 Apr 29, 2024 - Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings. 0

https://www.zacks.com/stock/news/2265282/biontech-bntx-to-report-q1-earnings-is-a-beat-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2265282 Apr 30, 2024 - On BioNTech's (BNTX) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its pipeline development now that the pandemic is over. 0

https://www.zacks.com/stock/news/2266535/sarepta-therapeutics-srpt-q1-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2266535 May 01, 2024 - Although the revenue and EPS for Sarepta Therapeutics (SRPT) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. 0

https://www.zacks.com/stock/news/2264268/what-s-in-store-for-adma-biologics-adma-in-q1-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2264268 Apr 29, 2024 - On ADMA Biologics' (ADMA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB. 0

https://www.zacks.com/stock/news/2266374/sarepta-therapeutics-srpt-q1-earnings-and-revenues-beat-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2266374 May 01, 2024 - Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 763.64% and 10.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.fool.com/earnings/call-transcripts/2024/05/01/sarepta-therapeutics-srpt-q1-2024-earnings-call-tr/?source=iedfolrf0000001 May 01, 2024 - SRPT earnings call for the period ending March 31, 2024. 0

https://www.zacks.com/stock/news/2267221/sarepta-srpt-q1-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2267221 May 02, 2024 - Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys. 0